List of Excipients in Branded Drug OMEPRAZOLE SODIUM BICARBONATE

Generic Drugs Containing OMEPRAZOLE SODIUM BICARBONATE

Company	Ingredient	NDC	Excipient
Cipla USA Inc	omeprazole sodium bicarbonate	69097-913	ALCOHOL
Cipla USA Inc	omeprazole sodium bicarbonate	69097-913	AMMONIA
Cipla USA Inc	omeprazole sodium bicarbonate	69097-913	BUTYL ALCOHOL
Cipla USA Inc	omeprazole sodium bicarbonate	69097-913	CROSCARMELLOSE SODIUM

What are the Most Frequently-Used Excipients in OMEPRAZOLE SODIUM BICARBONATE?

# Of NDCs	Excipient
2	ALCOHOL
1	AMMONIA
1	BUTYL ALCOHOL
2	CROSCARMELLOSE SODIUM

Last updated: August 9, 2026

Omeprazole sodium bicarbonate is a formulation-driven proton-pump inhibitor product in which sodium bicarbonate is the key enabling excipient. The commercial opportunity is not the omeprazole molecule itself, which is generic and mature, but the product architecture: immediate-release delivery, protection from gastric acid, suspension and capsule formats, dose flexibility, taste management, and manufacturing consistency. The strongest opportunities are differentiated generic products, hospital and institutional formulations, pediatric or swallowability-focused presentations, and lifecycle products that improve administration without changing the active ingredient.

Omeprazole Sodium Bicarbonate Excipient Strategy and Commercial Opportunities

What is omeprazole sodium bicarbonate?

Omeprazole sodium bicarbonate combines omeprazole, a proton-pump inhibitor, with sodium bicarbonate. The product is marketed in the United States as Zegerid and has been approved in capsule and oral-suspension dosage forms for adults and, for certain presentations, pediatric patients [1].

The formulation has two functional objectives:

1. Sodium bicarbonate raises gastric pH and protects omeprazole from acid degradation in the stomach.
2. The alkaline environment supports rapid release of omeprazole before intestinal absorption.

Traditional delayed-release omeprazole products use enteric-coated granules, pellets, or tablets. Omeprazole sodium bicarbonate products use an immediate-release approach in which sodium bicarbonate substitutes for, or reduces reliance on, enteric protection.

This creates a different excipient strategy from standard omeprazole capsules. The formulation depends on the amount, distribution, dissolution, and buffering capacity of sodium bicarbonate rather than only on polymeric enteric coating.

How does sodium bicarbonate function as the key excipient?

Sodium bicarbonate is both a pharmaceutical excipient and a pharmacologically relevant buffering agent in this product category. Its principal formulation functions are:

• Raising local and gastric pH.
• Limiting acid-mediated degradation of omeprazole.
• Supporting rapid omeprazole release.
• Reducing dependence on enteric-coated multiparticulates.
• Helping maintain drug stability during the initial gastric residence period.

The marketed 20-mg capsule contains 1,100 mg of sodium bicarbonate, while the 40-mg capsule contains 1,100 mg, according to the Zegerid prescribing information [1]. The oral suspension uses a different sodium bicarbonate quantity per dose. The large excipient-to-drug ratio has direct commercial implications: capsule size, powder flow, fill weight, patient sodium exposure, and packaging efficiency become central product-design constraints.

A development program should treat sodium bicarbonate as a critical material attribute rather than as an interchangeable filler. Relevant controls include:

• Particle-size distribution.
• Bulk and tapped density.
• Moisture content.
• Carbon dioxide generation under stressed conditions.
• Assay and alkalinity.
• Flowability during capsule filling.
• Compatibility with omeprazole and other excipients.
• Dissolution and pH performance.
• Microbial quality for powder or suspension products.

Changes in sodium bicarbonate grade can affect blend uniformity, capsule weight, dissolution, stability, and manufacturing yield. A supplier change may therefore require more than routine excipient qualification.

What other excipients are relevant to omeprazole sodium bicarbonate?

The broader excipient platform depends on dosage form and target market.

Capsule formulations

Capsules generally require excipients that support powder flow, content uniformity, and physical stability. Potential excipient classes include:

• Fillers and diluents to control bulk density.
• Glidants to improve powder flow.
• Lubricants to reduce manufacturing friction.
• Disintegrants where needed to promote rapid dispersion.
• Capsule-shell materials, typically gelatin or hypromellose.
• Colorants or imprinting systems for product identification.
• Moisture-control materials in packaging.

The formulation must preserve the alkaline microenvironment created by sodium bicarbonate. Acidic excipients may reduce buffer capacity and compromise omeprazole stability. Lactose, organic acids, acidic polymers, and certain hygroscopic materials require compatibility assessment rather than automatic exclusion.

Magnesium stearate, colloidal silicon dioxide, microcrystalline cellulose, and starch-based materials may be technically useful, but their levels should be minimized or optimized because they can alter powder flow, dissolution, fill weight, and stability.

Oral suspension formulations

Suspension products create a wider excipient opportunity. Candidate excipient functions include:

• Suspending agents.
• Wetting agents.
• Sweeteners.
• Flavors.
• Preservatives.
• Viscosity modifiers.
• pH adjusters.
• Antifoaming agents.
• Sachet or bottle-compatible packaging systems.

The principal development challenge is preserving a reproducible suspension without materially reducing omeprazole stability. A product may require reconstitution immediately before administration, or it may be supplied as a dry powder that is mixed with water.

Taste masking is commercially important because sodium bicarbonate can produce a salty or alkaline taste. Pediatric products and orally administered suspension products may require flavor systems, sweeteners, particle-size control, and viscosity adjustment. These changes can create differentiated intellectual property even when the active ingredient and general buffer concept remain conventional.

Pediatric formulations

Pediatric products must address dose flexibility, swallowing limitations, palatability, and age-specific administration. Potential commercial formats include:

• Lower-dose capsules.
• Sachets for reconstitution.
• Unit-dose oral suspension packets.
• Powder for pharmacy compounding.
• Ready-to-use oral suspensions.
• Sprinkle or dispersible products, subject to formulation and regulatory validation.

Sodium exposure must be evaluated in pediatric products. The amount of sodium bicarbonate required for acid protection can be substantial relative to the omeprazole dose. Labeling, patient population, renal considerations, and institutional use protocols can affect market acceptance.

What formulation patents protect omeprazole sodium bicarbonate products?

The most defensible intellectual-property value in omeprazole sodium bicarbonate products generally lies in formulation and manufacturing claims rather than in the active ingredient.

Potential claim categories include:

• Omeprazole combined with a specified amount of sodium bicarbonate.
• Immediate-release oral dosage forms.
• Specific omeprazole-to-bicarbonate ratios.
• Powder or suspension formulations.
• Reconstitution systems.
• Stabilized liquid formulations.
• Taste-masked suspensions.
• Low-moisture manufacturing processes.
• Packaging that limits moisture or carbon dioxide loss.
• Particle-size or granulation specifications.
• Specific dissolution or pharmacokinetic profiles.
• Pediatric dose presentations.
• Methods of treating acid-related disorders with the formulation.

The original Zegerid product was developed around an immediate-release omeprazole and sodium bicarbonate formulation. Relevant patent protection historically covered compositions, dosage forms, and methods of use. Because patent status changes through expiration, terminal disclaimers, maintenance-fee events, reexamination, litigation, and Orange Book delisting, the operative claims must be confirmed against the current FDA Orange Book and the USPTO patent record before a freedom-to-operate decision [2,3].

For a new entrant, expired composition claims do not eliminate risk. Later-filed patents can cover:

• Improved suspension stability.
• Alternative buffer concentrations.
• New dosage strengths.
• Administration to particular patient groups.
• Packaging or reconstitution systems.
• Manufacturing controls.
• Combination products.

A serious landscape should separate active composition patents from expired or abandoned applications, use patents, formulation patents, and manufacturing patents.

What is the Orange Book status of omeprazole sodium bicarbonate?

The FDA Orange Book identifies approved drug products, reference-listed drugs, therapeutic equivalence evaluations, and certain patents and exclusivity information [2]. Omeprazole sodium bicarbonate products should be assessed by NDA, dosage form, strength, and reference product rather than by active ingredient alone.

The regulatory analysis should distinguish:

Regulatory issue	Commercial significance
Reference-listed drug status	Determines the product used for ANDA comparison
Therapeutic equivalence rating	Affects substitution and payer acceptance
Listed patents	Defines potential Paragraph IV or Section VIII strategy
Pediatric exclusivity	Can delay approval or affect patent timing
NDA versus ANDA pathway	Determines the evidence and certification burden
Capsule versus suspension	May involve different reference products and bioequivalence issues
Strength-specific approval	Prevents automatic assumptions across 20-mg and 40-mg products

An abbreviated new drug application must address pharmaceutical equivalence, bioequivalence, labeling, manufacturing, and relevant patent certifications. A formulation that differs materially from the reference product may require additional comparative studies or a different regulatory pathway.

FDA approval of a generic omeprazole product does not automatically establish substitutability with omeprazole sodium bicarbonate. Delayed-release omeprazole and immediate-release omeprazole/sodium bicarbonate products have different dosage-form functions and may not be therapeutically interchangeable without the applicable FDA rating.

When does omeprazole sodium bicarbonate lose exclusivity?

The active ingredient omeprazole has long been off patent. The commercial exclusivity question therefore concerns product-specific formulation patents and regulatory exclusivity.

The original U.S. Zegerid regulatory exclusivity periods have expired. Current entry barriers are more likely to arise from:

• Product-specific patents that remain listed.
• Litigation settlements.
• Regulatory exclusivity attached to a particular product or use.
• Bioequivalence requirements.
• Manufacturing complexity.
• Commercial scale and payer contracting.

The relevant expiration date is not necessarily the expiration date of the earliest omeprazole patent. Analysts should identify every unexpired patent listed for the target reference product and determine whether it covers the proposed dosage form, strength, method of use, or manufacturing process.

What Paragraph IV challenges and generic entry risks exist?

A generic applicant may file a Paragraph IV certification if it believes a listed patent is invalid, unenforceable, or not infringed. The filing can trigger patent litigation and, in some circumstances, a 30-month stay of FDA approval under the Hatch-Waxman framework [4].

For omeprazole sodium bicarbonate, Paragraph IV risk is concentrated in formulation claims. The main litigation questions are likely to include:

• Whether the proposed product contains the claimed bicarbonate quantity.
• Whether the product is immediate release.
• Whether the proposed excipient system falls within the claim scope.
• Whether a process claim is infringed by the applicant’s manufacturing method.
• Whether the listed patent is valid after obviousness and written-description challenges.
• Whether a label carve-out avoids method-of-use claims.

Generic launch scenarios include:

1. Approval with no patent litigation, if no relevant unexpired patents remain.
2. Approval after a Paragraph IV notice and settlement.
3. Approval after litigation invalidates or narrows the asserted claims.
4. Approval with a Section VIII statement or skinny label for nonprotected uses.
5. Delayed launch because of formulation redesign, manufacturing scale-up, or unresolved patent claims.

The commercial risk is higher for a product that closely copies the reference formulation. A materially different suspension or packaging system may reduce literal infringement risk but increase bioequivalence and regulatory-development risk.

How strong is the patent estate for omeprazole sodium bicarbonate?

The patent estate is strongest when it combines composition, dosage-form, manufacturing, and use claims. A single expired composition patent provides limited protection against modern generic entry. A layered estate can still create negotiation leverage if later patents cover commercially necessary features.

A practical strength assessment should score each patent on:

Factor	Strong position	Weak position
Claim breadth	Covers broad formulation classes	Covers narrow excipient ratios
Remaining term	Multiple years remain	Near expiration
Validity	Supported by formulation data	Vulnerable to obviousness
Infringement visibility	Product characteristics are easy to prove	Process is difficult to detect
Regulatory relevance	Listed in the Orange Book	Unlisted process or ancillary patent
Design-around difficulty	Requires the same buffer architecture	Alternative buffers are feasible
Commercial necessity	Claim covers core product performance	Claim covers optional flavor or packaging

Sodium bicarbonate concentration, immediate-release behavior, and product stability are likely to be easier to design around than the general concept of using an alkaline buffer with omeprazole. Stronger protection may arise from validated performance parameters that competitors cannot readily avoid without losing product quality.

What manufacturing and IP barriers affect market entry?

Manufacturing is a more meaningful barrier than the chemical synthesis of omeprazole.

Key manufacturing risks include:

• Segregation of sodium bicarbonate from low-dose omeprazole.
• Powder-flow variability caused by high bicarbonate loading.
• Moisture uptake and degradation.
• Carbon dioxide generation during processing or storage.
• Capsule-fill weight and weight variation.
• Blend uniformity.
• Suspension sedimentation and redispersibility.
• Bottle or sachet moisture transmission.
• Stability after reconstitution.
• Scale-up differences between laboratory and commercial equipment.

A dry-blending process may be simple but can create content-uniformity problems because omeprazole is present at a much lower mass than sodium bicarbonate. Wet granulation may improve uniformity but introduces moisture and chemical-stability risk. Roller compaction may improve flow and reduce water exposure, but it can alter dissolution and compression behavior.

Packaging is part of the formulation strategy. High-barrier bottles, desiccants, foil sachets, and unit-dose systems can protect against moisture and simplify dose administration. Packaging patents may be commercially relevant where the product requires controlled reconstitution or extended in-use stability.

Which commercial opportunities exist for omeprazole sodium bicarbonate?

Differentiated generic capsules

A conventional generic capsule can compete on price, supply reliability, and payer coverage. The product may require less formulation differentiation but faces intense competition.

Potential advantages include:

• Smaller capsule size.
• Improved fill-weight consistency.
• Lower-cost bicarbonate sourcing.
• Better moisture protection.
• Additional strengths.
• More efficient bottle counts.
• Institutional packaging.

Oral suspension and pediatric products

Suspension products have greater differentiation potential because palatability, reconstitution, dose measurement, and stability are difficult to optimize. Pharmacies, hospitals, long-term-care facilities, and pediatric prescribers may value products that reduce compounding steps.

Potential claims and commercial features include:

• Unit-dose sachets.
• Ready-to-use suspension.
• Longer post-reconstitution shelf life.
• Improved taste.
• Lower sodium load per dose.
• Oral syringes or integrated dosing systems.
• Flexible dose titration.

Hospital and institutional supply

Hospitals may prefer unit-dose, shelf-stable products that reduce medication preparation. Demand can arise in intensive-care, perioperative, enteral-feeding, and inpatient settings where administration through feeding tubes or to patients unable to swallow tablets is important.

Tube administration must be validated for compatibility, clogging risk, adsorption, dose recovery, and flushing requirements. These data can support institutional adoption and may create a product-development advantage even if they do not create standalone patent protection.

Combination and lifecycle products

Commercial opportunities include combinations with:

• Antacids.
• Other gastrointestinal therapies.
• Symptom-directed products.
• Pediatric administration systems.
• Adherence-oriented packaging.

Combination products may trigger additional regulatory and patent complexity. The business case depends on whether the added product value justifies new clinical, stability, and labeling requirements.

How does omeprazole sodium bicarbonate compare with delayed-release omeprazole?

Attribute	Omeprazole sodium bicarbonate	Delayed-release omeprazole
Protection mechanism	Alkaline buffering	Enteric coating or enteric-coated multiparticulates
Release profile	Immediate release	Delayed release
Core excipient	High sodium bicarbonate load	Enteric polymer system
Manufacturing burden	Powder uniformity and bicarbonate control	Pellet coating and coating uniformity
Capsule size	Can be large because of bicarbonate	Depends on pellet and excipient loading
Suspension opportunity	Strong	Usually more complex
Taste considerations	Important for bicarbonate-containing products	Important for granules or suspensions
Sodium exposure	Product-specific and potentially substantial	Generally lower from formulation excipients
Differentiation	Buffer system, suspension, packaging	Coating, pellet, release profile

The two platforms should not be treated as interchangeable from a development perspective. Omeprazole sodium bicarbonate offers a potential advantage in rapid-release design and suspension development. Delayed-release products may offer more established manufacturing infrastructure and broader generic competition.

What are the revenue and market-entry considerations?

Revenue exposure depends on product format, channel, and degree of differentiation. A low-price capsule strategy can produce volume but is vulnerable to generic price erosion. A suspension or institutional product can support higher net pricing if it solves administration, stability, or preparation problems.

The main commercial variables are:

• Number of approved competitors.
• Therapeutic-equivalence rating.
• Payer and pharmacy substitution.
• Wholesaler concentration.
• Hospital group purchasing contracts.
• Reference-product brand loyalty.
• Manufacturing cost per dose.
• Sodium-related prescribing restrictions.
• Product shortages or supply interruptions.
• Pediatric and specialty-pharmacy demand.

A manufacturer should model at least three scenarios:

Scenario	Product position	Main risk
Commodity generic	Standard capsule at low price	Rapid price compression
Differentiated generic	Improved suspension, packaging, or administration	Development and regulatory cost
Specialty institutional product	Unit dose or administration-focused product	Limited market size and contracting pressure

The most defensible opportunity is usually a product with a clear administration benefit and manufacturing control advantage. A copycat capsule without cost or supply differentiation is less attractive.

What regulatory pathway applies to new products?

A conventional generic product may use the ANDA pathway if it matches the reference product in relevant dosage-form and performance characteristics. A novel suspension, combination, or materially different dosage form may require additional FDA interaction and potentially a 505(b)(2) application, depending on the product design and reference product [5].

Development should address:

• Comparative bioavailability.
• Food-effect considerations.
• Immediate-release performance.
• Buffer capacity and acid-protection testing.
• Stability under ICH conditions.
• In-use stability after reconstitution.
• Dose uniformity.
• Container-closure integrity.
• Microbial limits and preservative effectiveness.
• Administration through feeding tubes, where claimed.
• Labeling for sodium content and preparation instructions.

FDA guidance on oral drug products, bioequivalence, and inactive ingredients should be integrated into the development plan [5,6].

Key Takeaways

• Sodium bicarbonate is the central functional excipient in omeprazole sodium bicarbonate products.
• The product’s value comes from immediate-release acid protection, not from novel omeprazole chemistry.
• High bicarbonate loading creates capsule-size, sodium-exposure, powder-flow, and manufacturing challenges.
• Oral suspensions, pediatric products, unit-dose sachets, and institutional formats offer more differentiation than standard capsules.
• Formulation, manufacturing, packaging, and use patents should be analyzed separately.
• The active ingredient is mature; remaining exclusivity risk is product-specific.
• Paragraph IV risk depends on the current Orange Book listings for the selected reference product and dosage form.
• A strong commercial strategy requires validated stability, taste, dose flexibility, and administration data.
• The highest-value opportunity is a differentiated product that reduces preparation burden or expands use in patients who cannot swallow conventional dosage forms.

FAQs about omeprazole sodium bicarbonate excipient strategy

Is sodium bicarbonate an active ingredient or an excipient in Zegerid?

It is a functional buffering component that is listed as an inactive ingredient in the finished drug product but performs an essential formulation role by raising pH and protecting omeprazole from acid degradation.

Can sodium bicarbonate be replaced with another buffer?

A substitute buffer may be technically possible, but it could change stability, dissolution, pharmacokinetics, sodium exposure, labeling, and patent scope. The replacement would require formulation and regulatory evaluation.

Is omeprazole sodium bicarbonate suitable for pediatric development?

It can be suitable for pediatric products, particularly suspensions and flexible-dose formats. Palatability, dosing accuracy, sodium exposure, stability, and age-appropriate administration require specific development controls.

What is the main manufacturing risk for an omeprazole sodium bicarbonate capsule?

The main risk is achieving uniform distribution of a low-dose omeprazole throughout a high-mass sodium bicarbonate blend while controlling moisture, flow, fill weight, and stability.

Can a delayed-release omeprazole generic substitute for omeprazole sodium bicarbonate?

Substitution depends on FDA therapeutic-equivalence determinations and the applicable prescription and pharmacy rules. Dosage-form similarity and regulatory equivalence should not be assumed solely from the shared omeprazole active ingredient.

References

1. U.S. Food and Drug Administration. (2023). Zegerid (omeprazole and sodium bicarbonate) prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. United States Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/

4. U.S. Food and Drug Administration. (2017). Manual of policies and procedures: 5200.3, 30-month stays under the Hatch-Waxman amendments. https://www.fda.gov/

5. U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2). https://www.fda.gov/

6. U.S. Food and Drug Administration. (2018). Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. https://www.fda.gov/